

# Oncology Clinical Trials Market - 2024-2024

<https://marketpublishers.com/r/OF08CF8044CCEN.html>

Date: March 2026

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: OF08CF8044CCEN

## Abstracts

The Oncology Clinical Trials Market was valued at US\$ 19.73 billion in 2024 and is anticipated to reach \$ 252 billion by 2032, at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Oncology Clinical Trials Market.

This report delivers a comprehensive overview of the Oncology Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncology Clinical Trials Market. The Oncology Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2024.

Oncology Clinical Trials Market Scope:

By Phase Type

Phase I

Phase II

Phase III

## By Study Design

Interventional Studies

Observational Studies

Expanded access trials

## By Cancer Type

Lung Cancer

Breast Cancer

Prostrate Cancer

Skin Cancer

Others

## By End User

Biopharmaceutical Companies

Academic and Research Institutes

Others

## Key Players

AstraZeneca

Merck & Co., Inc

Gilead Sciences, Inc

F. Hoffmann-La Roche Ltd

Syneos Health

Daiichi Sankyo Company

Eli Lilly and Company

PharmaMar

Novocure

Pfizer Inc

## Major Highlights

This report delivers a comprehensive overview of the Oncology Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oncology Clinical Trials Market. The Oncology Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2024.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

- 3.1. Snippet by Phase Type
- 3.2. Snippet by Study Design
- 3.3. Snippet by Cancer Type
- 3.4. Snippet by End User
- 3.5. Snippet by Region

### **4. DYNAMICS**

- 4.1. Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. Rise in the prevalence of cancers
    - 4.1.1.2. Emerging immunotherapy approaches
  - 4.1.2. Restraints
    - 4.1.2.1. Complicated conditions and targeted treatments
    - 4.1.2.2. XX
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. PESTLE Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion

## **6. COVID-19 ANALYSIS**

### 6.1. Analysis of COVID-19

6.1.1. Scenario Before COVID

6.1.2. Scenario During COVID

6.1.3. Scenario Post COVID

### 6.2. Pricing Dynamics Amid COVID-19

### 6.3. Demand-Supply Spectrum

### 6.4. Government Initiatives Related to the Market During Pandemic

### 6.5. Manufacturers Strategic Initiatives

### 6.6. Conclusion

## **7. BY PHASE TYPE**

### 7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type

7.1.2. Market Attractiveness Index, By Phase Type

### 7.2. Phase I \*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 7.3. Phase II

### 7.4. Phase III

## **8. BY STUDY DESIGN**

### 8.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design

### 8.2. Market Attractiveness Index, By Study Design

### 8.3. Interventional Studies \*

8.3.1. Introduction

8.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 8.4. Observational Studies

### 8.5. Expanded access trials

## **9. BY CANCER TYPE**

### 9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

### 9.2. Market Attractiveness Index, By Cancer Type

### 9.3. Lung Cancer \*

- 9.3.1. Introduction
- 9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.4. Breast Cancer
- 9.5. Prostrate Cancer
- 9.6. Skin Cancer
- 9.7. Others

## **10. BY END USER**

- 10.1. Introduction
  - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 10.1.2. Market Attractiveness Index, By End User
- 10.2. Biopharmaceutical Companies\*
  - 10.2.1. Introduction
  - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Academic and Research Institutes
- 10.4. Others

## **11. BY REGION**

- 11.1. Introduction
  - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
  - 11.2.1. Introduction
  - 11.2.2. Key Region-Specific Dynamics
  - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type
  - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.2.7.1. U.S.
    - 11.2.7.2. Canada
    - 11.2.7.3. Mexico
- 11.3. Europe
  - 11.3.1. Introduction
  - 11.3.2. Key Region-Specific Dynamics
  - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type
  - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design

- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
- 11.4. South America
  - 11.4.1. Introduction
  - 11.4.2. Key Region-Specific Dynamics
  - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type
  - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.4.7.1. Brazil
    - 11.4.7.2. Argentina
    - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
  - 11.5.1. Introduction
  - 11.5.2. Key Region-Specific Dynamics
  - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type
  - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.5.7.1. China
    - 11.5.7.2. India
    - 11.5.7.3. Japan
    - 11.5.7.4. South Korea
    - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
  - 11.6.1. Introduction
  - 11.6.2. Key Region-Specific Dynamics
  - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Phase Type
  - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
  - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

#### 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

## **12. COMPETITIVE LANDSCAPE**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

## **13. COMPANY PROFILES**

- 13.1. AstraZeneca \*
  - 13.1.1. Company Overview
  - 13.1.2. Product Portfolio and Description
  - 13.1.3. Financial Overview
  - 13.1.4. Key Developments
- 13.2. Merck & Co., Inc
- 13.3. Gilead Sciences, Inc
- 13.4. F. Hoffmann-La Roche Ltd
- 13.5. Syneos Health
- 13.6. Daiichi Sankyo Company
- 13.7. Eli Lilly and Company
- 13.8. PharmaMar
- 13.9. Novocure
- 13.10. Pfizer Inc (LIST NOT EXHAUSTIVE)

## **14. APPENDIX**

- 14.1. About Us and Services
- 14.2. Contact Us

## I would like to order

Product name: Oncology Clinical Trials Market - 2024-2024

Product link: <https://marketpublishers.com/r/OF08CF8044CCEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OF08CF8044CCEN.html>